title: Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.
abstract: The aim of this study was to evaluate the mechanisms underlying weight gain induced by the atypical antipsychotic, olanzapine. We performed euglycemic, hyperinsulinemic clamp combined with indirect calorimetry on a 48-year-old male with antisocial personality disorder, alcohol dependence and paranoid ideation before and after one month of olanzapine (10 - 15 mg/day) therapy. The patient gave his informed, written consent for this study. The results were a weight gain of 6 kg and a decrease in both basal (from 1673 to 1613 kcal/24 h) and 3-hour (from 22.8 to 20.2 cal/kg fat free mass/min) energy expenditure. Serum thyroid hormone and high-density lipoprotein cholesterol levels decreased, and the triglyceride and low-density lipoprotein cholesterol levels increased. Insulin sensitivity did not change. We conclude that decreased basal energy expenditure may contribute to weight gain in olanzapine treatment.
authors.affiliation: Department of Psychiatry, University of Helsinki, Finland. matti.virkkunen@huch.fi
authors.forename: M
authors.initials: M
authors.lastname: Virkkunen
authors.forename: K
authors.initials: K
authors.lastname: Wahlbeck
authors.forename: A
authors.initials: A
authors.lastname: Rissanen
authors.forename: H
authors.initials: H
authors.lastname: Naukkarinen
authors.forename: A
authors.initials: A
authors.lastname: Franssila-Kallunki
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D002153:Calorimetry, Indirect; D004734:Energy Metabolism / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives; D011618:Psychotic Disorders / Q000188:drug therapy; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine